Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10740637rdf:typepubmed:Citationlld:pubmed
pubmed-article:10740637lifeskim:mentionsumls-concept:C0302592lld:lifeskim
pubmed-article:10740637lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:10740637lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:10740637lifeskim:mentionsumls-concept:C0600558lld:lifeskim
pubmed-article:10740637lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:10740637lifeskim:mentionsumls-concept:C0701185lld:lifeskim
pubmed-article:10740637pubmed:issue3lld:pubmed
pubmed-article:10740637pubmed:dateCreated2000-4-7lld:pubmed
pubmed-article:10740637pubmed:abstractTextNeoadjuvant chemotherapy (NAC) is currently used for the treatment of advanced cervical cancer by many institutions. We investigated the value of NAC followed by radical surgery and/or radiotherapy for patients with locally advanced cervical cancer. Sixteen patients with stage Ib2-IIIb cervical cancer were enrolled in this study. CPT-11 (60 mg/m2) in 500 m/5% glucose was given intravenously on Days 1, 8, and 15, before cisplatin (60 mg/m2) in 500 ml normal saline. The treatment was repeated every 4 weeks for 2 or 3 cycles. All patients were evaluable for response and toxicity. Two achieved a clinical complete response (CR), 11 had a partial response (PR), 2 had no change (NC) and 1 had progressive disease (PD), for an overall response of 81.3%. Neutropenia was observed in 100% (> grade 3: 70.6%) and diarrhea was recorded in 55.9% (> grade 3: 5.9%). The combination of CPT-11 and cisplatin in locally advanced cervical cancer is thus an active regimen with a manageable toxicity as a neoadjuvant chemotherapy.lld:pubmed
pubmed-article:10740637pubmed:languagejpnlld:pubmed
pubmed-article:10740637pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10740637pubmed:citationSubsetIMlld:pubmed
pubmed-article:10740637pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10740637pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10740637pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10740637pubmed:statusMEDLINElld:pubmed
pubmed-article:10740637pubmed:monthMarlld:pubmed
pubmed-article:10740637pubmed:issn0385-0684lld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:NishioSSlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:SugiyamaTTlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:NishidaTTlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:TomiokaYYlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:HiraiNNlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:KumagaiSSlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:KamuraTTlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:HasuoYYlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:FujiyoshiKKlld:pubmed
pubmed-article:10740637pubmed:authorpubmed-author:OotaSSlld:pubmed
pubmed-article:10740637pubmed:issnTypePrintlld:pubmed
pubmed-article:10740637pubmed:volume27lld:pubmed
pubmed-article:10740637pubmed:ownerNLMlld:pubmed
pubmed-article:10740637pubmed:authorsCompleteYlld:pubmed
pubmed-article:10740637pubmed:pagination429-35lld:pubmed
pubmed-article:10740637pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:meshHeadingpubmed-meshheading:10740637...lld:pubmed
pubmed-article:10740637pubmed:year2000lld:pubmed
pubmed-article:10740637pubmed:articleTitle[Neoadjuvant chemotherapy with cisplatin and CPT-11 for advanced cervical cancer].lld:pubmed
pubmed-article:10740637pubmed:affiliationDept. of Obstetrics and Gynecology, Kurume University, School of Medicine.lld:pubmed
pubmed-article:10740637pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10740637pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10740637pubmed:publicationTypeEnglish Abstractlld:pubmed